Cardiovascular Systems Releases 30-Day Results from COAST IDE Study in Late-Breaking Presentation at 2016 Cardiovascular Rese...
February 22 2016 - 2:00PM
Business Wire
- Information shared about the
Diamondback 360® Coronary Orbital Atherectomy System
(OAS) Micro Crown includes:
- 85% Procedural Success
- 85% 30-day Freedom from MACE
Rate
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), today released
30-day results from its Coronary Orbital Atherectomy System Study
(COAST) in a late-breaking presentation at the 2016 Cardiovascular
Research Technologies (CRT) conference in Washington, D.C.
The COAST study is CSI’s prospective, single-arm, multi-center,
global IDE trial to evaluate the safety and efficacy of the
company’s next-generation Micro Crown orbital atherectomy
technology in treating patients with severely calcified coronary
lesions. It follows the ORBIT II pivotal trial of the company’s
Diamondback 360® Coronary OAS Classic Crown, which received PMA
approval from the U.S. Food and Drug Administration (FDA) in 2013
as a primary treatment for severely calcified coronary arteries
when facilitating stent delivery. CSI completed COAST enrollment of
100 patients, including 74 patients at 12 sites in the United
States and 26 patients at five sites in Japan, in July 2015.
Dr. Richard A. Shlofmitz of St. Francis Hospital in Roslyn,
N.Y., presented the 30-day results including the primary endpoints
of procedural success and the freedom from major adverse cardiac
events (MACE), including target lesion revascularization (TLR) at
30 days after the procedure. Additional authors on the abstract
are: Dr. Shigeru Saito, Shonan Kamakura General Hospital, Kamakura,
Japan; Dr. Samin K. Sharma, Mount Sinai Medical Center, N.Y.; and
Dr. Gregg Stone, Columbia University Medical Center, N.Y.
COAST 30-day outcomes:
Procedural Success
85.0% Successful Stent delivery 99.0% Less
than 50% residual stenosis 99.0% In-hospital MACE
14.0%
Freedom from MACE (30-Day)
85.0% MI (defined as CK-MB >3x ULN) 14.0%
Non Q-wave
12.0%
Q-wave
2.0%
Target Vessel/Lesion Revascularization 1.0% TLR
1.0%
Cardiac Death 1.0%
“Adequate modification of severely calcified plaque is an
important step to achieve successful stent delivery and expansion,”
said Dr. Shlofmitz. “The Diamondback 360° Coronary OAS Micro Crown
is designed to engage tight lesions with distal sanding. The
results from the COAST IDE Study resulted in 99 percent successful
stent delivery and 85 percent freedom from 30-day MACE.”
More information about the study design is available at
www.ClinicalTrials.gov; identifier: NCT02132611.
About Coronary Artery Disease (CAD)CAD is a
life-threatening condition and a leading cause of death in men and
women in the United States. CAD occurs when a fatty material
called plaque builds up on the walls of arteries that supply blood
to the heart. The plaque buildup causes the arteries to harden and
narrow (atherosclerosis), reducing blood flow. The risk of CAD
increases if a person has one or more of the following: high blood
pressure, abnormal cholesterol levels, diabetes, or family history
of early heart disease. According to the American Heart
Association, 16.3 million people in the United
States have been diagnosed with CAD, the most common form of
heart disease. Heart disease claims more than 600,000 lives
in the United States each year. According to estimates,
significant arterial calcium is present in nearly 40% of patients
undergoing a percutaneous coronary intervention (PCI). Significant
calcium contributes to poor outcomes and higher treatment costs in
coronary interventions when traditional therapies are used,
including a significantly higher occurrence of death and major
adverse cardiac events (MACE).
About Cardiovascular Systems, Inc.Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company
focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital
Atherectomy Systems treat calcified and fibrotic plaque in arterial
vessels throughout the leg and heart in a few minutes of treatment
time, and address many of the limitations associated with existing
surgical, catheter and pharmacological treatment alternatives. The
U.S. FDA granted 510(k) clearance for the use of the
Diamondback Orbital Atherectomy System in peripheral arteries
in August 2007. In October 2013, the company
received FDA approval for the use of the Diamondback
Orbital Atherectomy System in coronary arteries. The Stealth 360®
Peripheral Orbital Atherectomy System (OAS) received CE Mark
in October 2014. To date, nearly 235,000 of CSI’s devices have
been sold to leading institutions across the United States.
The Coronary OAS Micro Crown is limited by federal law to
investigational use and is currently not commercially available in
the United States.
For more information, visit the company’s website
at www.csi360.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160222005931/en/
Cardiovascular Systems, Inc.Mark Sullivan,
651-900-7077msullivan@csi360.comorPadillaCRTMatt Sullivan,
612-455-1709matt.sullivan@padillacrt.com
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024